Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

1. Filgotinib for treating moderate to severe rheumatoid arthritis

Filgotinib for treating moderate to severe rheumatoid arthritis Filgotinib for treating moderate to severe rheumatoid arthritis T echnology appraisal guidance Published: 24 February 2021 www.nice.org.uk/guidance/ta676 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration (...) to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents 1 Recommendations 4 2 Information about filgotinib 7 Marketing authorisation indication 7 Dosage

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Upadacitinib (Rinvoq) - moderate to severe active rheumatoid arthritis (RA)

Upadacitinib (Rinvoq) - moderate to severe active rheumatoid arthritis (RA) 1 Published 08 February 2021 1 SMC2315 upadacitinib 15mg prolonged-release tablet (Rinvoq®) AbbVie Ltd 15 January 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission upadacitinib (Rinvoq®) is accepted (...) for restricted use within NHSScotland. Indication under review: for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate. SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy

2021 Scottish Medicines Consortium

3. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation Full Text available with Trip Pro

Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you (...) requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} There is limited evidence and much uncertainty in relation to the clinical and cost-effectiveness of enzyme-linked immunosorbent assay-based therapeutic drug monitoring in rheumatoid arthritis. {{author}} {{($index , , , , , , , , , , & . Irina A Tikhonova 1, 2

2021 NIHR HTA programme

4. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY Full Text available with Trip Pro

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) : 10.1093/rheumatology/keaa770. Online ahead of print. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA. 2 HEOR Immunology, AbbVie Inc., North Chicago, IL, USA. 3 Aurora Rheumatology and Immunotherapy Center, Franklin, WI, USA. 4 Centre for Musculoskeletal Research

2021 EvidenceUpdates

5. The effect of physical exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis

The effect of physical exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis The effect of physical exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis , , , , Affiliations Expand Affiliations 1 School of Nursing, Peking University, Beijing, P.R. China. 2 Department of Rheumatology and Immunology, The People's Hospital of Peking University, Beijing, P.R. China. 3 Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, P.R. China. 4 Health Science Centre for Evidence-Based Nursing: A Joanna Briggs Institute Centre of Excellence, Peking

2021 EvidenceUpdates

6. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study

Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation Ann Rheum Dis Actions . 2020 Dec 11;annrheumdis-2020-218758. doi: 10.1136/annrheumdis-2020-218758. Online ahead of print. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands. 2 Division of Pharmacoepidemiology

2021 EvidenceUpdates

7. Upadacitinib for treating severe rheumatoid arthritis

Upadacitinib for treating severe rheumatoid arthritis Upadacitinib for treating severe rheumatoid arthritis T echnology appraisal guidance Published: 9 December 2020 www.nice.org.uk/guidance/ta665 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Upadacitinib for treating severe rheumatoid arthritis (TA665) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about upadacitinib 7 Marketing authorisation 7 Dosage in the marketing authorisation 7 Price 7 3 Committee

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Non-surgical Periodontal Treatment in Individuals with Periodontal Disease and Rheumatoid Arthritis (RA) Leads to Improvements in Markers of RA Disease Activity

Non-surgical Periodontal Treatment in Individuals with Periodontal Disease and Rheumatoid Arthritis (RA) Leads to Improvements in Markers of RA Disease Activity UTCAT3453, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Non-surgical Periodontal Treatment in Individuals with Periodontal Disease and Rheumatoid Arthritis (RA) Leads to Improvements in Markers of RA Disease Activity Clinical Question For patients (...) with rheumatoid arthritis (RA) and periodontal disease (PD), does non-surgical periodontal therapy impact the patient’s rheumatic health based on biochemical and clinical parameters of RA? Clinical Bottom Line With non-surgical periodontal treatment in patients with RD and RA, there is a positive effect on multiple biochemical and clinical parameters of RA; this conclusion is based on the results of three systematic reviews. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID

2020 UTHSCSA Dental School CAT Library

9. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme Full Text available with Trip Pro

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) of print. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme , , , , , , , , , , Affiliations Expand Affiliations 1 Metroplex Clinical Research Center, Dallas, Texas, USA arthdoc@aol.com. 2 Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands. 3 Oregon Health and Science University, Portland, Oregon, USA. 4 Centro Universitario Central Paulista, São Paulo, Brazil. 5 University of Occupational and Environmental

2020 EvidenceUpdates

10. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naive Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial Full Text available with Trip Pro

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naive Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Arthritis Rheumatol Actions . 2020 Jul 8;72(10):1607-1620. doi: 10.1002/art.41384. Online ahead of print. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial , , , , , , , , , Affiliations Expand Affiliations

2020 EvidenceUpdates

11. Dietary interventions with or without omega-3 supplementation for the management of rheumatoid arthritis: a systematic review protocol Full Text available with Trip Pro

Dietary interventions with or without omega-3 supplementation for the management of rheumatoid arthritis: a systematic review protocol Dietary interventions with or without omega-3... | HRB Open Research ') search clear search menu close clear Search Dietary interventions with or without omega-3 supplementation for... ALL Metrics - Views Downloads How to cite this article Raad T, George E, Griffin A et al. Dietary interventions with or without omega-3 supplementation for the management (...) of rheumatoid arthritis: a systematic review protocol [version 1; peer review: awaiting peer review] . HRB Open Res 2020, 3 :72 ( ) NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first All fields are required. I thought this article from HRB Open Research (https://hrbopenresearch.org) would be of interest

2020 HRB open research

12. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) Full Text available with Trip Pro

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) . Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Metroplex Clinical Research Center, Dallas, TX, USA. 2 Genentech, Inc, South San Francisco, CA, USA. 3 Division of Immunology and Rheumatology, Stanford University, Stanford, CA, USA. 4 Centro Médico Privado De Reumatología, Tucumán, Argentina. 5 University of Belgrade Medical School, Belgrade, Serbia. 6 Bogomolets

2020 EvidenceUpdates

13. Filgotinib (Jyseleca) - rheumatoid arthritis

Filgotinib (Jyseleca) - rheumatoid arthritis Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/420605/2020 EMEA/H/C/005113 Jyseleca (filgotinib) An overview of Jyseleca and why (...) it is authorised in the EU What is Jyseleca and what is it used for? Jyseleca is a medicine for treating adults with moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue to cause inflammation and pain in joints. Jyseleca is used alone or with another medicine, methotrexate, after treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or causes unacceptable side effects. DMARDs

2020 European Medicines Agency - EPARs

14. Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades Full Text available with Trip Pro

Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades | SpringerLink Search Search SpringerLink Search Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades Incidence (...) and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades , , & , volume 7 , pages 685 – 702 ( 2020 ) 631 Accesses 1 Altmetric Abstract Introduction Over the past several decades, management of rheumatoid arthritis (RA) has evolved significantly, but few studies have examined the real-world impact of these changes on orthopaedic surgery in patients with RA. This systematic review assessed total hip arthroplasty (THA) incidence

2020 Rheumatology and therapy

15. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. (Abstract)

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain.To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy.Retrospective cohort (...) associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk.National Institute of Arthritis and Musculoskeletal and Skin Diseases.

2020 Annals of Internal Medicine

16. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for two systematic reviews and meta-analyses Full Text available with Trip Pro

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for two systematic reviews and meta-analyses Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for two systematic reviews and meta-analyses | Research Square Browse Tools & Services Your Cart This preprint is under consideration at Systematic Reviews . A preprint is a preliminary version of a manuscript that has not completed peer review (...) at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for two systematic reviews and meta-analyses Bruna de Oliveira Ascef, Matheus Oliveira Almeida, Ana Cristina de

2020 Research Square

17. Effect of down-regulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: a protocol for a systematic review and meta-analysis Full Text available with Trip Pro

Effect of down-regulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: a protocol for a systematic review and meta-analysis Inplasy Protocol 792 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

18. HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis: a systematic review and meta-analysis Full Text available with Trip Pro

HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis: a systematic review and meta-analysis HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis: a systematic review and meta-analysis Binbin Xie, Jiang He, Yong Liu, Ting Liu, Chaoqun Liu Binbin Xie Jinan university Jiang He Southern Medical University Yong Liu Anhui Medical University Ting Liu Jinan University Chaoqun Liu

2020 Research Square

19. The Effectiveness of Acupuncture and Moxibustion for Rheumatoid Arthritis: A Protocol of an Overview of Systematic Reviews and Meta-analysis Full Text available with Trip Pro

The Effectiveness of Acupuncture and Moxibustion for Rheumatoid Arthritis: A Protocol of an Overview of Systematic Reviews and Meta-analysis The Effectiveness of Acupuncture and Moxibustion for Rheumatoid Arthritis: A Protocol of an Overview of Systematic Reviews and Meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior (...) to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol The Effectiveness of Acupuncture and Moxibustion for Rheumatoid Arthritis: A Protocol of an Overview of Systematic Reviews and Meta-analysis Genhua Tang, Jun Xiong, Siyuan Zhu, Zhiying Zhong, Jun Chen, Lunbin Lu, Han Guo, Xingchen Zhou, Hao Fan Genhua Tang Jiangxi University

2020 Research Square

20. Rituximab (Riximyo) - Non?Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis

Rituximab (Riximyo) - Non?Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2020 Health Canada - Drug and Health Product Register